NCT07247279 Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
| NCT ID | NCT07247279 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Rare Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2025-12-23 |
| Primary Completion | 2029-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in routine clinical practice in Russia.
Eligibility Criteria
Inclusion Criteria: 1. Adults (≥18 years) diagnosed with generalized MG positive for acetylcholine receptor (AChR) antibodies. 2. Provision of signed and dated written informed consent. Exclusion Criteria: 1. Participants currently enrolled in clinical studies for treatment of gMG. 2. Ocular MG only.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.